Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 43, Issue -, Pages 27-36
Publisher
Wiley
Online
2015-12-01
DOI
10.1111/apt.13436
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study
- (2014) K. Kato et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
- (2014) Dirk Gevers et al. Cell Host & Microbe
- Is Rifaximin Effective in Maintaining Remission in Crohn's Disease?
- (2014) Anca Olivia Jigaranu et al. DIGESTIVE DISEASES
- Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis
- (2014) Joshua Terc et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
- (2014) Aleksandar D. Kostic et al. GASTROENTEROLOGY
- Rifaximin: beyond the traditional antibiotic activity
- (2014) Fiorella Calanni et al. JOURNAL OF ANTIBIOTICS
- Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature
- (2014) Yael Haberman et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report
- (2014) Dan Turner et al. Journal of Crohns & Colitis
- The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications
- (2014) Jason R. Goldsmith et al. JOURNAL OF GASTROENTEROLOGY
- Complex host genetics influence the microbiome in inflammatory bowel disease
- (2014) Dan Knights et al. Genome Medicine
- Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease
- (2013) Ioannis Koutsounas et al. CURRENT DRUG METABOLISM
- Drosophila as a model for intestinal dysbiosis and chronic inflammatory diseases
- (2013) Kyung-Ah Lee et al. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY
- Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome
- (2013) Dan Knights et al. GUT
- Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
- (2013) Pieter Dewint et al. GUT
- Bile Acid Malabsorption Deactivates Pregnane X Receptor in Patients with Crohn’s Disease
- (2013) Junichi Iwamoto et al. INFLAMMATORY BOWEL DISEASES
- Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States
- (2013) Millie D. Long et al. INFLAMMATORY BOWEL DISEASES
- National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States
- (2013) Geoffrey C. Nguyen et al. Journal of Crohns & Colitis
- Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis
- (2013) Caroline Schrodt et al. PLoS One
- From genetics of inflammatory bowel disease towards mechanistic insights
- (2013) Daniel B. Graham et al. TRENDS IN IMMUNOLOGY
- Use of antibiotics in the treatment of Crohn’s disease
- (2013) Maria Lia Scribano WORLD JOURNAL OF GASTROENTEROLOGY
- The role of antimicrobials in Crohn’s disease
- (2013) Pramodini B Kale-Pradhan et al. Expert Review of Gastroenterology & Hepatology
- Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg- -Naphthylamide-Inhibitable Efflux Pumps
- (2012) V. Kothary et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population
- (2012) Michael D. Kappelman et al. DIGESTIVE DISEASES AND SCIENCES
- Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease
- (2012) Belgin Dogan et al. INFLAMMATORY BOWEL DISEASES
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
- (2012) Luke Jostins et al. NATURE
- Acute and chronic pouchitis—pathogenesis, diagnosis and treatment
- (2012) Bo Shen Nature Reviews Gastroenterology & Hepatology
- Pregnane X receptor as a target for treatment of inflammatory bowel disorders
- (2012) Jie Cheng et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
- (2011) Khurram J Khan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells
- (2011) Andrea Mencarelli et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
- (2011) Cosimo Prantera et al. GASTROENTEROLOGY
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial
- (2010) Toshifumi Ohkusa et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells
- (2010) Andrea Mencarelli et al. BIOCHEMICAL PHARMACOLOGY
- The role of mucosal immunity and host genetics in defining intestinal commensal bacteria
- (2010) Jonathan Hansen et al. CURRENT OPINION IN GASTROENTEROLOGY
- Genetics and Environmental Interactions Shape the Intestinal Microbiome to Promote Inflammatory Bowel Disease Versus Mucosal Homeostasis
- (2010) R. Balfour Sartor GASTROENTEROLOGY
- Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases
- (2010) Daniel N. Frank et al. INFLAMMATORY BOWEL DISEASES
- Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system
- (2010) Simone Maccaferri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation
- (2010) J. Cheng et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Management of Crohn's Disease in Adults
- (2009) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
- (2009) E. L. Brown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases
- (2009) Christopher D Packey et al. CURRENT OPINION IN INFECTIOUS DISEASES
- European evidence-based Consensus on the management of ulcerative colitis: Current management
- (2008) S.P.L. Travis et al. Journal of Crohns & Colitis
- PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
- (2008) Bin Zhang et al. PHARMACOGENOMICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started